Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
MARINUS PHARMACEUTICALS, INC. (MRNS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
05/11/2023 8-K Quarterly results
03/07/2023 8-K Quarterly results
11/07/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results",
"Corporate investor presentation, dated November 2021"
08/10/2021 8-K Quarterly results
Docs: "Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results · Anticipate initiating a Phase 3 trial of adjunctive ganaxolone in tuberous sclerosis complex in Q3 2021, targeting first patient enrolled during Q4 2021; continue to expect topline Phase 2, open label data in Q3 2021 · European Medicines Agency is expected to accept accelerated assessment of ganaxolone for the treatment of seizures associated with CDKL5 deficiency disorder ; Marinus plans to submit a marketing authorization application to the EMA by the end of Q3 2021 · Received notice of allowance from the U.S. Patent and Trademark Office for refractory status epilepticus dosing and method of treatment patent application · U.S. Food and Drug Administration indic...",
"Marinus Pharmaceuticals. All Rights Reserved I Corporate Presentation August 2021"
03/09/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "Sasha Damouni Ellis Vice President, Investor Relations"
08/12/2020 8-K Quarterly results
05/04/2020 8-K Quarterly results
Docs: "Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results",
"I GANAXOLONE PHASE 1 PHASE 2 PHASE 3 ANTICIPATED MILESTONES"
11/08/2019 8-K Quarterly results
Docs: "MARINUS PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER FINANCIAL RESULTS"
08/08/2019 8-K Quarterly results
Docs: "Amended and Restated Employment Agreement, between the Company and Scott Braunstein, M.D",
"MARINUS PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER FINANCIAL RESULTS"
05/06/2019 8-K Quarterly results
Docs: "MARINUS PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS"
10/30/2018 8-K Quarterly results
Docs: "Marinus Pharmaceuticals PROVIDES business UPDATE and THIRD quarter 2018 financial results"
08/02/2018 8-K Quarterly results
Docs: "Marinus Pharmaceuticals PROVIDES business UPDATE and second quarter 2018 financial results"
05/02/2018 8-K Quarterly results
Docs: "Marinus Pharmaceuticals PROVIDES business UPDATE and first quarter 2018 financial results"
10/31/2017 8-K Quarterly results
08/01/2017 8-K Quarterly results
Docs: "Marinus Pharmaceuticals PROVIDES business UPDATE and reports second quarter 2017 financial results Data from Studies in Rare Pediatric Epilepsies and Severe Postpartum Depression Expected in 2nd Half"
05/02/2017 8-K Form 8-K - Current report
11/21/2016 8-K Form 8-K - Current report
08/09/2016 8-K Form 8-K - Current report
05/02/2016 8-K Quarterly results
Docs: "Marinus Pharmaceuticals PROVIDES business UPDATE and reports first quarter 2016 financial results"
10/29/2015 8-K Quarterly results
Docs: "Marinus Pharmaceuticals PROVIDES business UPDATE and reports third quarter 2015 financial results"
08/04/2015 8-K Quarterly results
Docs: "Upcoming Milestones · Complete enrollment in ongoing Phase 3 clinical trial evaluating ganaxolone in adults with drug-resistant focal onset epileptic seizures and announce top-line data in the first quarter of 2016. · Announce initial data from Phase 2 proof-of-concept, open-label clinical trial in PCDH19 female pediatric epilepsy. · Complete preclinical and manufacturing activities for ganaxolone IV and announce results and first stage clinical plans. · Complete Phase 2 proof-of-concept investigator-sponsored clinical trial evaluating ganaxolone as a treatment for behaviors in Fragile X Syndrome later this year, with top-line data released early 2016. Second Quarter Financial Update At June 30, 2015, the Company had cash, cash equivalents and investments of $40.4 milli..."
03/17/2015 8-K Quarterly results
Docs: "MARINUS PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND REPORTS"
11/13/2014 8-K Quarterly results
Docs: "MARINUS PHARMACEUTICALS, INC. SELECTED FINANCIAL DATA ASSETS Cash and cash equivalents $ 47,105,069 $ 10,037,123 Other assets 455,809 1,786,822 Total assets $ 47,560,878 $ 11,823,945 LIABILITIES AND STOCKHOLDERS' EQUITY Total current liabilities 1,335,386 2,365,770 Notes payable 2,000,000 — Total liabilities 3,335,386 2,365,770 Total stockholders' equity 44,225,492 Total liabilities and stockholders' equity $ 47,560,878 $ 11,823,945 Three Months Ended September 30, Nine Months Ended September 30, 2014 2013 2014 2013 Expenses: Research and development $ 1,568,740 $ 1,008,469 $ 6,537,617 $ 3,020,884 General and administrative 868,301 313,421 1,827,658 869,207 Loss from operations Change in fair value of warrant liability 794,342 91,583 1,191,514 91,583 Interest income 3,794 6,368 6,330 13,..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy